IGY Presentation Jan 2010 NML WPG

BEYOND ANTIBIOTICS -TREATING VIRUSES & BACTERIA PATHOGENS WITH SPECIFIC ANTIBIODIES - AND ELIMINATING THE SIDE

EFFECTS IN THE PROCESS.

JANUARY 26TH - NATIONAL MICROBIOLOGY LABORATORY

Presenter

Presentation Notes

Terry Dyck has been working with the Management and Executive team of IRI Separation since August of 2007. Hired originally as the Financial Advisor to the company, Terry has taken on a greater role in working with IRI management to put into place many of the company’s current commercialization and distribution initiatives. He has also opened many of the doors for the company allowing IRI Separation to become a key industry participant in future scientific work aimed toward strengthening the immune system. After talking to many industry experts, and becominXg an insider within the company, Terry has taken the lead role in bringing IRI Separation into full scale production of Immunoglobulin. In early 2009, this lead to the decision to buy the assets of IRI Separation and delist the currently publicly traded company from the TSX. There is a letter of intent signed by both parties, agreeing to both the sale of all assets to the new company, IGY Life Sciences inc.

IGY Immune Technologies & Life Sciences Inc.

SAFE HARBOUR STATEMENTS

The information in this presentation is being made available to you and a limited number of other prospective investors on a confidentialbasis, solely for the purpose of your consideration of an investment in securities under a securities purchase agreement, and suchinformation may not be used for any other purpose.

The information contained herein has been obtained from IGY Immune Technologies and Life Sciences Inc. (the “Company”) and fromsources believed by the Company to be reliable. The Company makes no representations or warranties, express or implied, as to theaccuracy or completeness of this information. The Company expressly disclaims any and all liability from any untrue statements oromissions, which may be contained in this presentation or any other written or oral communication transmitted or made available to aprospective investor. Only those particular representations made in a securities purchase agreement shall have any legal effect.

Certain statements in this presentation, such as those concerning the Company’s business strategy, products, revenues and capitalrequirements, and other statements regarding matters that are not historical facts, and the Company’s financial projections included herein,are “forward-looking” statements (as defined in the securities act of 1933). Because such forward-looking statements includerisk and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements.

During the course of your evaluation, all inquiries and other communications are to be made only to employees or representatives of theCompany. Accordingly, you agree not to directly or indirectly discuss with, or offer to, any third party a participation in a possible transactionor any other form of joint investment or acquisition by you and such third party without The Company’s prior written consent.

Presenter

Presentation Notes

Today’s Agenda


PRESENTATION OVERVIEW

OverviewWhat We Do

Our Mission

The Trillion Dollar Health and Wellness Market

Building Immune Systems and Treating Specific World Health Problems

The Technology

Market Segments:

Medicines

Functional Foods

Agribusiness & Packaged Consumer Meat Producers

Cosmeceuticals

Corporate Structure

Strategic Timeline

Leverage Through Partnerships

Financial Forecasts

Financing Objectives

Management Team, Consultants, Advisory Board, Board Of Directors

Presenter

Presentation Notes

Today’s Agenda


WHAT WE DO

IGY Immune Technologies and Life Sciences specializes in the extraction of polyclonal antibodies, a type of antibody that are derived from chicken eggs for use as nutraceuticals and pharmaceuticals for human and animal consumption.

Immunoglobulins are powerful antibodies produced in healthy humans and other animals to fight infections and prevent disease. Egg yolks contain immunoglobulin IgY, the functional equivalent of immunoglobulin IgG which makes up 75% of the immunoglobulin found in healthy human plasma.

Our proprietary technology and processes makes it possible to create health products to strengthen and supplement your

natural immune system against certain types of bacterial, viral and autoimmune ailments.

Presenter

Presentation Notes

Today’s Agenda


OUR MISSION

IgY Immune Technologies and Life Sciences Inc. is in the business of designing specific antibodies through natural sources and purifying them through its proprietary extraction methods. By introducing specific antibodies to the animal kingdom, we have the ability to prevent disease, save lives and reduce our dependence on antibiotics.

By improving the body’s natural immune system, like never before, we can improve the lives of millions suffering from viral, bacterial, and autoimmune diseases.

By preventing the spread of disease, we can save hundreds of billions in valuable tax resources; allowing governments to redirect their resources into other areas of science, to lower the costs of healthcare systems around the world and ultimately, bring IgY medicine to the developing world.

By arming veterinary science with improved methods to farm our agriculture and aquaculture industries, we will create a stronger food network and at the same time, a safer drinking water system by reducing it’s over use of antibiotic drugs.

By extending these same specific antibodies to our family pets, they can live longer, healthier lives for everyone to enjoy.

By putting into effect the knowledge of immunologists and microbiologists around the world, our scope of science to be discovered is incredible.

By achieving all of this, our stakeholders will be pioneers in medical science and earn a valuable share in our financial successes.

The Cure is in the Prevention. IgY for Life.

Presenter

Presentation Notes

IGY Life Sciences seeks to develop life-saving treatments for the human body by using the immune system to heal itself. By providing (preventing?) disease we save lives, valuable tax revenues and improve the quality of life for all men, women and children. The science of IGY will lessen our dependence on antibiotics in our food system and our medical system and stem the need to develop new antibiotics in a world of ever-increasing resistant pathogens created through the overuse of these drugs. IgY Life Sciences Inc. is in the business of designing specific antibodies through natural sources and purifying them through its proprietary extraction methods. By introducing specific antibodies to the animal kingdom, we have the ability to prevent disease, save lives and reduce our dependence on antibiotics. By improving the body’s natural immune system, like never before, we can improve the lives of millions suffering from viral, bacterial, and autoimmune diseases. By preventing the spread of disease, we can save hundreds of billions in valuable tax resources; allowing governments to redirect their resources into other areas of science, to lower the costs of healthcare systems around the world and ultimately, bring IgY medicine to the developing world. By arming veterinary science with improved methods to farm our agriculture and aquaculture industries, we will create a stronger food network and at the same time, a safer drinking water system by reducing it’s over use of antibiotic drugs. By extending these same specific antibodies to our family pets, they can live longer, healthier lives for everyone to enjoy. By putting into effect the knowledge of immunologists and microbiologists around the world, our scope of science to be discovered is incredible. By achieving all of this, our stakeholders will be pioneers in medical science and earn a valuable share in our financial successes. The Cure is in the Prevention. IgY for Life.


THE TRILLION DOLLAR HEALTH & WELLNESS MARKET

THE MARKET OPPORTUNITY

Public health awareness continues to shift towards disease prevention.

Boosting immune systems will become an increasingly important focus as our population base ages.

Dietary supplements and vitamins, already used extensively, don't contain the antibodies needed to fight off or prevent disease.

Presenter

Presentation Notes

Only Ig can boost immune systems, and until now, there hasn't been an economical source of concentrated Ig available.


THE TRILLION DOLLAR HEALTH & WELLNESS MARKET

“The biggest story of 2008 is the accelerating pace of the formulation of nutraceuticals into functional foods. Beverages and dairy products are the leading delivery vehicles but consumers appetite for more natural and clinically demonstrated healthy ingredients in their food has become a mainstream driving force for new product development and product line extension.” -Nutraceutical World, State of the Industry Review (Dec. 2008)

Presenter

Presentation Notes

“The biggest story of 2008 is the accelerating pace of the formulation of nutraceuticals into functional foods. Beverages and dairy products are the leading delivery vehicles but consumers appetite for more natural and clinically demonstrated healthy ingredients in their food has become a mainstream driving force for new product development and product line extension.” Nutraceutical World, State of the Industry Review (Dec. 2008) www.feelgoodinside.ca www.minutemaid.ca Headline: Jones Soda gets exclusive rights to natural ingredient from Japan for use in new type of energy drink. June 2007 Jones has made an agreement with Pharma Foods Inc. to access their proprietary product called GABA. This is an anti-stress neurotransmitter. “Securing the rights to Pharma GABA is the key step in our development of an entirely new type of Jones Energy beverage.” Peter Van Stolk, President and CEO of Jones Soda. The energy beverage category is estimated to be over $6 billion in sales expected to exceed $10 billion by 2010. source: Jones Soda news release, June 2007


Alexander FlemingDiscovered Penicillin, 1928

80 YEARS OF ANTIBIOTICS

BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS

“In his 1945 Nobel Prize address, Alexander Fleming warned that itwas easy to produce microbes resistant to his discovery, penicillin. Simply expose them to concentrations of the drug was insufficient to kill them.”

John Hopkins Magazine, John Hopkins University

Presenter

Presentation Notes

What medicine has been unable to do effectively is create a supplement or drug that will rebuild the capacity of our immune system and repair the natural deterioration of our immune system as we age. Antibiotics Invented in 1928 by Alexander Fleming, penicillin was hailed as a medical miracle for which the medical world of that time had been waiting. 50% of the worlds antibiotics are used in healthy animals Over use of antibiotics has lead to a host of other problems in the medical world, which now awaits for the next ‘miracle’.



Viral Bacteria

Autoimmune

•World health concerns are our concerns. More than ever before, viruses spread at alarmingly fast rates due to global trade and travel.

Presenter

Presentation Notes

World health concerns are our concerns. More than ever before, viruses spread at alarmingly fast rates due to global trade and travel. June 11th, 2008 – the World Health Organization declared the alert level to 6 and declaring it a pandemic.



•36,000 U.S. deaths and 200,000 hospitalizations attributed to influenza each year. Direct and indirect cots of the average flu season amount to approximately $10 billion. The World Bank estimated that a severe influenza pandemic would cost the U.S. more than 600 Billion dollars, potentially leading to a major global recession.

Presenter

Presentation Notes

36,000 U.S. deaths and 200,000 hospitalizations attributed to influenza each year. Direct and indirect cots of the average flu season amount to approximately $10 billion. The World Bank estimated that a severe influenza pandemic would cost the U.S. more than 600 Billion dollars, potentially leading to a major global recession. Source: Immune Support – Investing in Prevention by Sean Moloughney, Nutraceuticalworld.com, 2008



June 24, 2009

Here is the spread of Swine Influenza on a live basis. This map clearly shows that we have a major health concern on our hands as this new pathogen is spreading quickly in what is normally the off season for influenza.

Presenter

Presentation Notes

Here is the spread of Swine Influenza on a live basis. This map clearly shows that we have a major health concern on our hands as this new pathogen is spreading quickly in what is normally the off season for influenza. More than 70 countries are now reporting cases of human infection. While the pandemic level 6 phase is a reflection of the spread of the novel H1N1 and not the severity of the new strain, scientists believe that the situation may worsen as the new bug continues to mutate. http://www.cdc.gov/h1n1flu/ http://flutracker.rhizalabs.com/



August 3, 2009

• More than 70 countries are now reporting cases of human infection. Because of global trade, which we are all dependent upon, there are no ‘safe’ zones from the effects of a new pandemic.

Presenter

Presentation Notes

Here is the spread of Swine Influenza on a live basis. This map clearly shows that we have a major health concern on our hands as this new pathogen is spreading quickly in what is normally the off season for influenza. More than 70 countries are now reporting cases of human infection. While the pandemic level 6 phase is a reflection of the spread of the novel H1N1 and not the severity of the new strain, scientists believe that the situation may worsen as the new bug continues to mutate. http://www.cdc.gov/h1n1flu/ http://flutracker.rhizalabs.com/



“I suffer no illusions that this will be an easy process. It will be hard. But I also know that nearly a century after Teddy Roosevelt first called for reform, the cost of our health care has weighed down our economy and the conscience of our nation long enough. So let there be no doubt; health care reform cannot wait, it must not wait, and it will not wait another year.”

- President Barack Obama, February 2009.

“Under the proposed Preservation of Antibiotics for Medical Treatment Act, or PAMTA, newly-developed antibiotics couldn’t be given to farm animals unless they were sick. The casual use of already-established drugs would be restricted.”

- Brandon Keim, Wired Magazine, July 21, 2009

Presenter

Presentation Notes

More than just an ally in taking a new approach to healthcare, we have been approached by Dr. George Carlo to discuss how IGY Life Sciences can participate in the new health care regime of President Obama. Dr. Carlo is



Focusing in the immune system is a natural evolution in fight against diseases. Medical science is recognizing the importance of strengthening innate immune system and reducing reliance on antibiotics.

Presenter

Presentation Notes

We are at an inflection point in health sciences and IGY has a 10 year head start on the competition in terms of our technology. That translates into 10 years of potential exponential growth which translate into exceptional shareholder returns.


THE TECHNOLOGY

Breakthrough

IGY’s ground-breaking technology opens the wide doorway to a whole new science.

Presenter

Presentation Notes

According to Activate Your Immune System, by Leonid Ber and Krolyn Gazella, the immune system holds the key to optimum health as it determines if one will get the flu, how long allergy symptoms will last and even if one will succumb to the ravages of cancer or aids. In large part, the immune system will dictate how one lives and how one will die.


Antibody ExtractionIGY Immune Technologies & Life Sciences Inc

High Resolution Yolk Byproducts(Patented)

IG Antibodies

THE PROCESS

THE TECHNOLOGY

Presenter

Presentation Notes

After separating the yolk from the white, our technology effectively removes, refines and concentrates the Immunoglobulin from the eggs. It took over ten years of work, generating a number of I.P. patents in the process. In addition, key elements of the process were never patented, and are held as intellectual secrets by the company. Duplicating our process would conceivably take any competitor another decade to do. By that time, our company will have cornered the world’s supply on commercial eggs. And should a competitor duplicate the process, find or produce their own eggs, they will have one other major barrier to over come. Removing the Ig(Y) from the egg changes the molecular make-up of the egg slightly. The yolk becomes what is known as a HIGH RATIO YOLK, and has been patented by our Company. Reintroducing HRY back into the food chain will violate our patents, and force the competitor to increase their costs as they discard it into the animal feed market.


ANTIBODY YIELD FROM HENS

THE TECHNOLOGY

A laying hen can produce approximately 300 eggs annually and the volume of one egg yolk is approximately 15 ml.

This could supply close to 100g of antibody per hen per year.

Each Egg contains approximately 3-5mg IgY per ml of yolk (70-100mg of total IgY antibody depending upon the size of the egg)

Of this total and depending on the concentration level required for commercial effectiveness, our technology can generate as little as10% or as much as 75% antibody against a specific antigen.

Presenter

Presentation Notes

After separating the yolk from the white, IRI Separation simply removes, refines and concentrates the Immunoglobulin from the eggs. It took over ten years of work, and they now hold over fifty-six patents on the process. In addition, key elements of the process were never patented, and are held as intellectual secrets by the company. Duplicating IRI’s process would conceivably take any competitor another decade to do. By that time, our company will have cornered the world’s supply on commercial eggs. And should a competitor duplicate the process, find or produce their own eggs, they will have one other major barrier to over come. Removing the Ig(Y) from the egg changes the molecular make-up of the egg slightly. The yolk becomes what is known as a HIGH RESOLUTION YOLK, and has been patented by IRI Separation. Reintroducing HRY back into the food chain will violate IRI’s patents, and force the competitor to increase their costs as they discard it into the animal feed market.


ADVANTAGES OF ANTIBODIES FROM EGG YOLKS OVER MAMMALIAN ANTIBODIES

THE TECHNOLOGY

a. A single egg contains as much antibody as an average bleed from a rabbit. In addition, egg collection is simple and noninvasive. Eggs are generally laid on a daily basis, whereas a rabbit may only be bled once every 2-3 weeks.

b. Chickens require only a one month immunization regimen to obtain high titers of polyclonal antibody. To ensure a rabbit is producing high titers of antibody, the immunization procedure requires up to 2-3 months.

c. Similar amounts of antigen are required to immunize chickens and rabbits, but daily egg collection occurs over a month and titers generally remain high during this period. A rabbit may be bled only once every 2-3 weeks and the amount of antibody contained in the sera is equivalent to the amount of antibody in a single egg.

d. Because the phylogenetic distance between birds and mammals is great, chickens are very useful for producing antibodies against conserved mammalian proteins. Typically, 1-5% of rabbit sera will be comprised of antibodies against a specific mammalian antigen. About 2-10% of a chicken egg yolk is comprised of antigen-specific antibodies. In addition, very highly conserved mammalian proteins sometimes fail to elicit an immune response in rabbits but antibodies against these proteins are often successfully produced in the avian system.

Presenter

Presentation Notes

After separating the yolk from the white, IRI Separation simply removes, refines and concentrates the Immunoglobulin from the eggs. It took over ten years of work, and they now hold over fifty-six patents on the process. In addition, key elements of the process were never patented, and are held as intellectual secrets by the company. Duplicating IRI’s process would conceivably take any competitor another decade to do. By that time, our company will have cornered the world’s supply on commercial eggs. And should a competitor duplicate the process, find or produce their own eggs, they will have one other major barrier to over come. Removing the Ig(Y) from the egg changes the molecular make-up of the egg slightly. The yolk becomes what is known as a HIGH RESOLUTION YOLK, and has been patented by IRI Separation. Reintroducing HRY back into the food chain will violate IRI’s patents, and force the competitor to increase their costs as they discard it into the animal feed market.


Viral infections include:

All colds and flu

Most coughs

Most sore throats, and

Usually involve several parts of the body

THE TECHNOLOGY

IgY Works on Both Viral and Bacteria Infections

Bacterial infections include:

Strep throat

Urinary tract infections

Most ear infections

Some sinus infections, and

Are usually localized at a single point in the body

Presenter

Presentation Notes

Antibiotics can not kill viruses. A virus is an infectious agent, smaller than bacteria, which requires the cells of a living organism to grow or reproduce. Viruses cause a variety of infectious diseases, among them the common cold, diarrhea, chicken pox, yellow fever, most childhood respiratory diseases and the majority of infections of the upper respiratory passages. Final tests will be completed by the Office of Clinical Research – St. Boniface General Hospital Research Centre by fall of 2009 to definitively prove that “Ig(Y) improves the innate immune system.” Bottom line is that the immune system is the only cure for the common cold virus – and with a stamp of approval from this internationally recognized laboratory, IGY Life Sciences will be able to claim that they hold the cure for the common cold. While antibiotics are critical to the health care system, they are to all extent indiscriminative, and kill off both the good and the bad bacteria. Antibodies derived from eggs can be tailor-made for Specific Bacteria or Viruses.


THE PROCESS OF MAKING IGY – ON A COMMERCIAL SCALE

160,000 eggs per day.

ONE KILO of 50% Pure IgY is produced by 350,000 birds laying 10,500 eggs per month.

Presenter

Presentation Notes

350,000 Birds will be required to provide the required Yolk to produce 1,000 Kilo of 50% pure Antibodies per month. Two years Projections are for 5,000 Kilo of General Antibodies by 2009, together with 1,000 plus Kilo of Specific Antibodies. (equates to Yolk from some 2,150,000 Birds) and these projections could be conservative.



Eggs are broken at a Canadian Food Inspected egg station, and the unused portion is put back into the food production.



… then mixed with water and centrifuged to create a Water Soluble Fraction, containing the desired IgY.

Presenter

Presentation Notes

Our process involves mixing the HS Yolk with water – Immunoglobulin Antibodies are water soluble – and then separating off the water from the residual yolk. Many prior art methods of immunoglobulin isolation involve precipitation and the use of precipitating agents, such as ethanol, polyethylene glycol, lyotropic salts such as copper-sulfate, ammonium sulfate and ammonium phosphate, and caprylic acid. The prior art does not teach a commercial scale method of immunoglobulin isolation from egg yolks which does not require such chemical agents, nor an IgY product which is free of the residues of such chemical agents



•The prototype facility was over $10 million in design and installation.•Capable of producing up to 2,000 kg per month of IgY.

Presenter

Presentation Notes

The water (WSF) is then further processed using our patented technology to purify and concentrate the Immunoglobulin antibodies. 50,000 Kilo of Yolk Yields approx. 420 Kilo of 50% pure Antibodies 50,000 Kilo of Yolk also produces 16,800 Kilo of our Simplimix Residual Dried Egg Product. (or 45,000 kilo of liquid)


ISOLATION OF IGY FROM EGG YOLKResults: SDS-PAGE

IgY

Rm rt+w1 w2 el

Presenter

Presentation Notes

This is a third party review using an SDS-Page analysis, clearly defining the IgY in the test.


App. 60 % purity

IgYResults: Size exclusion chromatography

ISOLATION OF IGY FROM EGG YOLK

Presenter

Presentation Notes

Our technology is the perfection of an Ion Exchange system that separates IgY from egg Yolk as describe in our Patent: Title: A METHOD FOR COMMERCIAL ISOLATION OF EGG YOLK IGY, ITS PRODUCT, AND USES OF THE PRODUCT�Abstract: A method for extraction and purification of IgY from immune avian egg yolk comprising diluting a mixture of liquid egg yolk and liquid egg white in treated water; stirring the diluted mixture to obtain an egg mixture; separating the egg mixture into a first water soluble fraction, an un-separated mixture fraction, and a first separated lipophilic fraction; separating the first water soluble fraction; the un-separated mixture fraction, and the first separated lipophilic fraction; centrifuging the unseparated mixture fraction until it separates into a second water soluble fraction and a second separated lipophilic fraction; adding the second water soluble fraction to the first water soluble fraction to form a combined water soluble fraction; passing the combined water soluble fraction through an ion exchange adsorption column containing IgY-adsorbent beads to adsorb IgY; eluting the adsorbed IgY of from the ion exchange adsorption column with an eluting solution to obtain an eluant; filtering the eluant of through a first membrane filtration system to obtain a 4% to 25% IgY concentrate; and drying the IgY concentrate to obtain a 40% to 98% IgY isolate, as well as a food-safe IgY isolate obtained and use of a food-safe IgY isolate in an edible product.


EFFECTIVENESS OF IGY FOR SALMONELLA

THE TECHNOLOGY

Presenter

Presentation Notes

The results are measurable, effective and have been independently verified.


COMPETITIVE ADVANTAGES

THE TECHNOLOGY

Higher concentration of IgY (traditional 5% purity vs. 25% or >)

Fats are removed

No Cholesterol

Pharmaceutical grade

Tasteless and odorless

Can be “designed” for a variety of applications

Can be used in an aerosol

No competitive technology

Comprehensive patents on intellectual property

.


INTELLECTUAL PROPERTY PROTECTION

THE TECHNOLOGY

Our Company’s value lies in our ability to continuously generate new IP protection for IgY. We are regularly adding new patents to our existing portfolio.

Patent approvals are sought internationally for ingredients and processes and for products that are developed.

We have chosen not patent certain key elements of our process for added protection.


MANUFACTURING & PRODUCTION

THE TECHNOLOGY

Control over egg supply chain

Eggs are the most economical and practical solution as chickens lay eggs

regularly, so there is a continual source of antibody

Agreements secured with suppliers

economical and practical solution deal to the leftover egg byproduct

Presenter

Presentation Notes

A real key to our success will be in the system’s ability not to disrupt the balance of existing egg productions with an over supply of new egg product. This is achieved because our process allows the unused portoion


MARKET SEGMENTS

COMMERCIAL APPLICATIONS

Our commercial applications fall across 4 primary sectors which means we can grow our product base and revenue streams against any cyclical variations.

Presenter

Presentation Notes

Antibiotics can not kill viruses. A virus is an infectious agent, smaller than bacteria, which requires the cells of a living organism to grow or reproduce. Viruses cause a variety of infectious diseases, among them the common cold, diarrhea, chicken pox, yellow fever, most childhood respiratory diseases and the majority of infections of the upper respiratory passages. Final tests will be completed by the Office of Clinical Research – St. Boniface General Hospital Research Centre by fall of 2009 to definitively prove that “Ig(Y) improves the innate immune system.” Bottom line is that the immune system is the only cure for the common cold virus – and with a stamp of approval from this internationally recognized laboratory, IGY Life Sciences will be able to claim that they hold the cure for the common cold. While antibiotics are critical to the health care system, they are to all extent indiscriminative, and kill off both the good and the bad bacteria. Antibodies derived from eggs can be tailor-made for Specific Bacteria or Viruses.


MARKET SEGMENTS: MEDICINES

IGY SPECIFIC - CLOSTRIDIUM DIFFICILE (C.DIFFICLE)

Ig(Y) specific for Clostridium Difficile Bacteria.

Under development with Dr. Michelle Alfa, University of Manitoba and St. Boniface Hospital

Expected combined phase I and II trials to be completed within 24 months, and a marketable pharmaceutical ready for 2012

Expected to generate over a Billion dollars of revenue in North America alone.

Dr. Alfa has already proven the viability of generating the antigens from the eggs, the problem remained commercial ability to produce an Ig(Y) Specific, which has now been solved.

Presenter

Presentation Notes

The second IGY Specific will become our first Pharmaceutical. Under development with Dr. Michelle Alfa, University of Manitoba and St. Boniface Hospital, a specific Ig(Y) to the Clostridium Difficile Bacteria. Expected phase I and II trials to be completed within 24 months, and a marketable pharmaceutical ready for 2012, will generate over a Billion dollars of revenue in North America alone. Dr. Alfa has already proven the viability of generating the antigens from the eggs, the problem remained commercial ability to produce an Ig(Y) Specific, which has now been solved. While Dr. Alfa is working on the C. Difficile problem, the lab at IRI has been contracted to produce a Specific for the H5N1 Avian Influenza for Japan. And since we started this venture, swine flu has emerged as a world health issue looking for a solution.


Potentially lethal cases of C. Difficile “rocketed” from 1990s to 2004

Cases had increased from 1,000 in 1990 to over 35,000 in 2003

44,488 cases of C. Difficile in > 65 year olds in 2004.

Good new stats here on C. Dif. with 7,000 cases per day, and 300 mortalities per day.

$51.5 million in health care costs, per day in the United States. That is $18.8 Billion per year in costs. This just for C. Diff. not to mention MSRA.

A single occurrence of CDI adds about $3,700 to a hospital bill and can mean three or more additional nights in the hospital.

BBC News. http://news.bbc.co.uk/2/hi/health/4186834.stm

LETHAL HOSPITAL BUG CASES ROCKET, UNITED KINGDOM

MARKET SEGMENTS: MEDICINES

CLOSTRIDIUM DIFFICILE (C.DIFFICLE)


MARKET SEGMENTS: FUNCTIONAL FOODS



Multi-Million dollar letter of intent signed December 25th, 2008.

Pharma Foods markets a variety of Ig(Y) products.

Majority of Asians and Mexicans suffer from HP bacteria.

Second part of agreement to produce H5N1 (avian flu) antibody.

Current processes provide approximately 5% purity of H. Pylori IGY. Our process provides 50-75% purity of H. Pylori IGY.

PHARMA FOODS INTERNATIONAL CO., LTD

Discussions with Pharma Company in China to produce a H.Pylori pharmaceutical.

Presenter

Presentation Notes

The first functional food ingredient to be produced will be for the Helico Pylori Bacteria, the root cause of many stomach ulcers. A global problem as over 50% of the planet’s population is infected by this disease. Most prevalent in developing countries, where water purification and cleaning vegetables remains an issue. The first contract for Ig(Y) H. Pylori comes from Japan to supply on a month basis, 200 kg of the Ig(Y) specific, at a rate of $2,000 per Kg. That will generate a $400,000 monthly cash-flow to IGY International once the production has been fully implemented. 200 Kg remains a very small percentage of the potential for the Asian market. According to the introduction notes of the 2007 China / Korea / Japan H. Pylori Conference, over 80% of their population suffers from this bacteria. Through our agent SCITI K.K., Pharma Foods will begin to replace their existing source of Ig(Y) H. Pylori from Germany. This product which is a de-fatted dried egg yolk has about a 4% concentration. Our product is 50% concentration. Moreover, the existing product has issues with appearance, the amount that needs to be consumed to be effective, odor and taste. Consumers will be happy to convert to the IGY Life Sciences H. Pylori as there is no taste, no odor, the concentrations are higher, therefore smaller quantities can be consumed. Pharma Foods sees this contract as a cash incentive for IGY Life Sciences, and will use it as leverage to reach there end goal, which is to acquire a antigen for the H5N1 Avian Influenza. The far east is extremely fearful of the continued development of this pathogen, which continues to evolve. They have developed technology that will allow them to spray out antibodies onto air filters, and place those filters in chicken barns to protect the flocks. Now that Swine Flu H1N1 has arrived, the same technology can be used for that virus. The Canadian Armed Forces have successfully stopped the H5N1 influenza using an inhaled version of the Ig(Y) H5N1 antibodies. They used that on swine and have effectively proven a protocol for delivering the antigen.

http://images.google.ca/imgres?imgurl=http://web.1.c2.audiovideoweb.com/1c2web3536/IgYYogurtinJAPAN - Credit - Pharma Food International Co., Ltd..jpg&imgrefurl=http://portal.acs.org/portal/PublicWebSite/pressroom/newsreleases/WPCP_012358&usg=__k9y4wb1uZIurOwmxeSrKkvD728c=&h=2448&w=3264&sz=1769&hl=en&start=2&sig2=lbF3YDuwfTmWAogDhdOKLA&tbnid=fiucbdmfI-4ZNM:&tbnh=113&tbnw=150&prev=/images?q=gut+yogurt+korea&hl=en&rlz=1T4ADBF_enCA317CA318&ei=nMtnSs_iLozflAfRgrDECQ�



http://www.pharmafoods.co.jp

Presenter

Presentation Notes

Here is a page straight from Pharma Foods web sight where they illustrate the process of removing the H. Pylori from the chicken egg. The product is yellow, as the consumer eats a dried egg yolk which contains the H. Pylori antigens. Not only does our process go one step beyond the current method, and separate the H. Pylori IgY from the yolk, our concentrates are 50 – 75% pure IgY, compared to the current 5% IgY content. The contract will be for 200 kg per month, with a 40 kg minimum at $2,000 per kg. Once the product is being produced, we will gather information on how it is being accepted within the population and make use of that at the International China / Japan / Korea H. Pylori Conference. H. Pylori is such a wide spread problem in the east that this conference is held every year to discuss new products and methods of treatment. Because the incidence is so high in these countries, they also suffer from the world’s highest incidence of stomach and intestinal cancers, a direct result of the constant inflammation from the H. Pylori bacteria. (source: H. Pylori conference web site) Pharma Foods request for 200 kg per month represents only 10% of their current sales of H. Pylori to Korea. We anticipate gaining most of that market share, and expanding into the Japanese market which currently shy's away from the existing product due to its taste and smell.


MARKET SEGMENTS: AGRIBUSINESS AND PACKAGED CONSUMER MEATS

Presenter

Presentation Notes

The Japanese have already developed an air filtration system to be used within the agricultural world using IgY antibodies for H5N1, Avian Influenza. The same could be developed for swine flu, to be used within the hog industry. In a private meeting with John Webb, lead scientist for Maple Leaf Foods in 2008, using IgY within their industry is a must have product. They have committed to be the first customers for any such product we can develop for them. The meeting was originally establish to solve their Listeria issue. Our contacts at Honeywell are very interested in looking at IgY as the next step for their air handling units, which are used not only in the airline industry, but in hospitals, cruise ships, but currently not in the agriculture.


MARKET SEGMENTS: COSMECEUTICALS

The cosmeceuticals market is forecasted to reach $21 billon by 2012

Sales of natural body care products are thriving with 14% growth in 2007 and annual compound growth of 57% since 2004

Skin care, hair care and colour cosmetic cosmeceuticals showed an overall 25% gain in the retail sector between 2003 and 2007

THE COSMECEUTICALS MARKET



Our Acne Product is an antibody tailored skin treatment. The antibodyspecifically targets the primary acne bacteria called Propionibacterium acnes orP. Acnes for short. Our acne treatment inactivates P. Acnes and therebyremoves the major cause of skin inflammation and disease. Without P. Acnesthe skin will heal and new lesions will not occur.

Before Treatment

After Treatment

A natural and a safe alternate to Antibiotic Treatment for Acne



1. Cleansing Mousse : Contains Natural Oceanic Clay, Herbs and Vitamin E to protect and maintain the skin’s health while natural emulsifiers and scrubbing beads remove makeup and soils effectively.

2. Natural Oceanic Clay mask with IgY: Anti-Acne Clay Mask with IgY helps combat blemishes and blackheads in a double action through the combined forces of our Natural Oceanic Clay and APA - IgY.

3. Moisturizing Cream with IgY: This anti-acne moisturizing cream is formulated as a treatment for prevention of acne skin infections caused by Propionibacterium acne. Our unique antibody treatment – APA-IgY (Anti Propionibacterium Acnes-IgY) penetrates the skin and destroys the Propionibacterium Acne-bacteria that is common among all forms of acne, and prevents the appearing of blackheads and blemishes. Panthenol and Sunflower Oil moisturizes the skin. This beneficial formula completes the treatment of acne while maintaining the healthy condition of the skin.

The IGY Skincare Program is a complete system of three products



Proactiv annual worldwide sales are about $850 million, 70 percent of which are in the United States.

“Right now, we own acne,” said Greg Renker, a chief executive of Guthy-Renker, the direct-response television company that sells Proactiv“

New York Times, October 2007

INFOMERCIAL STRATEGY

Presenter

Presentation Notes

"Proactiv has become a phenomenon by transforming the way consumers think about pimples. The brand captured public attention by hiring stars for its infomercials like Vanessa Williams, Jessica Simpson and Sean Combs to lay bare their valiant struggles to attain flawless skin, effectively turning acne into a celebrity malady. But the company’s real innovation was repositioning mild breakouts from a routine annoyance that a dab of Clearasil might fix to a preventable condition, like cavities, requiring vigilant daily upkeep.

http://flaggedforfollowup.typepad.com/.shared/image.html?/photos/uncategorized/2007/10/18/proactive_jessica_simpson.jpg�


STRATEGIC TIMELINE

Presenter

Presentation Notes

We are fortunate to have a number of very rare and key elements come into play that we believe will lower the overall risk of rolling out our products: The first is the fact that a deal for raw product has been signed with Japan. Expected delivery of the product should be within four months, assuming no other delays in financing. The second major benefit is the fact that we have attracted Globayne Marketing International. They will remove the risk of hiring a major sales force, breaking into difficult major markets, paying for shipping and for a marketing campaign. They are very much a turn key operation, from which we collect a royalty, and leave our resources to build other markets. We have already attracted the likes of Eugene Melnyk, former President of Biovail, and one of Canada’s preeminent Billionaires from the bio-tech industry. We have had four meetings to discuss his new company’s involvement in the C. Difficile project, and while we believe that we could complete the project without his team, they bring decades of expertise in this area and will open many doors very quickly for the company. No formal agreement has been established during this financing period. The product is a stand-alone element, that will become a household name within the food and science industry. It offers all sorts of joint venture opportunities to partner with the likes of Maple Leaf Foods Ltd, the Toronto Maple Leafs, Honeywell Systems and many other industry recognized brand names that can expand their market share by labeling their products to read: Contains Muno Boost Ig(Y). Product Roll out Strategy Q3 - Begin C. Difficile development. Q4 - Cash flow Positive with H. Pylori contract. Q1 - Canadian roll out of Muno-Boost. Q2 - Build on Joint Venture agreements.


FedNor

Provincial Health Care Ministries

National Research Counsel, IRAP program

Ironwood Clay Company

University of Manitoba

St. Boniface Research Centre

LEVERAGE RESOURCES THROUGH PARTNERSHIPS

Presenter

Presentation Notes

Over the past eighteen months we have approached several potential partners for either distribution, product development or product placement. Established is a written distribution contract with Globayne International Marketing for key products coming from our nutraceutical division. We have held a number of meetings with Dr. Michelle Alfa who holds a number of patents relating to pharmaceutical compositions for treating gastrointestinal disorders including, but not limited to: Clostridium difficile, E. Coli, Listeria monocytogenes and other common enteric pathogens. Trimel Bio Pharma is Eugene Melnyk’s new Biotechnology company and have been acquiring assets for the past twelve months. While we are pleased with their level of interest, we have stopped soliciting their interest until our financing is completed. Our friends at Globayne have opened the door to have a sit down with Brian Burke, the new GM of the Maple Leafs. NHL Hockey players suffer from fatigue and stress due to their physical exhaustion. A natural partnership for a product like Muno Boost. Through our own strong political affiliations, the Premier of Ontario, Dalton McGuinty, the Minister of Health for Alberta, the Honorable Ronald Liepert, and the Minister of Health for B.C., the Honorable Kevin Falcon wish to learn more about our C. Difficile project and the Swine Flu project.


THE OPPORTUNITY LIES IN OUR LEADERSHIP

While the current budget is set for cosmeceutical and nutraceutical applications, the opportunity for the National Microbiology Lab lies in a joint effort to create the first pharmaceutical IgY product.

A C. difficile IgY Specific remains our top priority. Much of the phase I & II clinical work has been completed

by the SBRC. Steps to move forward include acquiring a government

approved vaccine for C. difficile, producing a test sample of IgY Specific C. difficile, completing the requirements for human testing.


ELISA C.difficile

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

62.5 125 250 500 1000 2000 4000 8000 [IgY] (ng/mL)

A(405nm)

Sigma IRI 27067 IRI 07067 IRI 27067 Eggcellent Extract blank (diluent) 3% gelatin coated vs 27067 extract 3% gelatin coated vs 27067

THE OPPORTUNITY LIES IN OUR LEADERSHIP


IGY C. DIFFICILE SPECIFIC – SAVE LIVES & MONEY

Currently, 300 people per day die as a result of C. difficile related causes in the USA everyday.

The cost to the US health-care system is $51.5 million per day.

The average cost of a stay in a Canadian hospital is $1,350, escalating to $2,500 per day in an isolation room.

We estimate that at 75% of the patient load in a health care facility taking C. difficile IgY Specific antibodies, at $3.50 per day would save roughly $16 billion in health care costs in North America and 120,000 lives annually.


IMAGINE THE POSSIBILITIES

Candida albicans Rotavirus Streptococcus mutans Listeria monocytogenes Parvovirus Celiac and colitis Cystic fibrosis Staphylococcal enterotoxin B As a tool in proteomics


Terry N. Dyck President, CEO

Sharad Mistry Chief Financial Officer

John Mason Chief of Research

David Mason Chief of Operations

MANAGEMENT TEAM


Dr. Stu Richie Canadian Poultry Consultants Ltd.

Roger Upton, President Ironwood Clay Company

Ian Cooke Facilities Engineer

Ameann DeJohn Ameann Solutions, CA

Bob Jones, Principle Scientia Advisors

John Henderson, President Brain Box Communications

CONSULTANTS


Ron Bayne President of GloBayne

Dr. John Webb Director of Science, Maple Leaf Foods

Ken Boshcoff Governmental Affairs

Dr. Frank Mauro Periodontist

Dr. Sheetal Sapra Dermatology

Dr. Keith Ly Dermatology

Dr. Jeanette Jacknin Dermatology

ADVISORY BOARD

Presenter

Presentation Notes

Ron Bayne is the President of Globayne Marketing. He was the former CMO and President of IRI Separation, so he knows the company and the marketing opportunities very well. He has over 40 years of retail marketing experience in the food and drug industry. Mr. Bayne sits on the Council of CMO’s International. The council consists of 3,000 Chief Marketing Officers Worldwide. A person cannot apply to sit on the council or be elected, they have to be appointed based on past business performance. Mr. Bayne sits with the World Leaders in Marketing including, but not limited to, the CMO’s of G.E., Pepsi, Coke, Wal-Mart, Yahoo etc. Only 1% of all CMO’s in the world sit on the council, and Mr. Bayne is the only member of the council from British Columbia.


LEGAL TEAM

Michael Strickland, corporate affairs Bust & Partners, Thunder Bay, ON

Jay Lefton, securities law Ogilvy Renault, Toronto

Stephen Burri, Intellectual Property Miller Thomson, Vancouver

John Cameron, BDO Dunwoody Auditors, Thunder Bay


Terry N. Dyck, President and CEO

Kevin Nephin

Dr. Brian Scott

Rashid Ahmed

pending

BOARD OF DIRECTORS


A New Beginning…Boosting the Immune System,

Prevention is the Cure.

QUESTIONS AND ANSWERS

Presenter

Presentation Notes

Thank you for your time, your interest and your advice.

IGY Presentation Jan 2010 NML WPG

Documents

missionigy immune technologies

immune systems w

specific antibodies

forwardlooking statements

bodys natural immune

certain statements

untrue statements

specific world health